본문으로 건너뛰기
← 뒤로

Quinoline-5,8-dione CDC25 inhibitors: Potent anti-cancer agents in leukemia and patient-derived colorectal organoids.

1/5 보강
European journal of medicinal chemistry 📖 저널 OA 6.1% 2022: 0/1 OA 2023: 0/2 OA 2024: 1/6 OA 2025: 2/65 OA 2026: 11/154 OA 2022~2026 2026 Vol.301() p. 118215
Retraction 확인
출처

Narwanti I, Yu ZY, Sethy B, Zheng PL, Cheng LH, Tsai KK

📝 환자 설명용 한 줄

Cell division cycle 25 (CDC25) phosphatases are critical activators of cyclin-dependent kinases (CDKs) and guardians of genome integrity, making them attractive anticancer targets.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Narwanti I, Yu ZY, et al. (2026). Quinoline-5,8-dione CDC25 inhibitors: Potent anti-cancer agents in leukemia and patient-derived colorectal organoids.. European journal of medicinal chemistry, 301, 118215. https://doi.org/10.1016/j.ejmech.2025.118215
MLA Narwanti I, et al.. "Quinoline-5,8-dione CDC25 inhibitors: Potent anti-cancer agents in leukemia and patient-derived colorectal organoids.." European journal of medicinal chemistry, vol. 301, 2026, pp. 118215.
PMID 41045697 ↗

Abstract

Cell division cycle 25 (CDC25) phosphatases are critical activators of cyclin-dependent kinases (CDKs) and guardians of genome integrity, making them attractive anticancer targets. Building on the quinoline-5,8-dione scaffold NSC663284 (6a), we synthesized derivatives with diverse C-6/C-7 alkylamino side chains. Structure-activity studies identified D3a/D3b (2-(4-methylpiperidin-1-yl)ethylamino) and D11a/D11b (2-(dimethylamino)ethylamino) as the most potent, exhibiting low-submicromolar inhibition of CDC25. In cell-based assays, these compounds suppressed leukemia (IC 0.21-1.22 μM) and colorectal cancer (IC 0.13-1.50 μM) viability, with reduced toxicity in normal colonic epithelial cells. Mechanistically, these derivatives blocked CDC25-mediated CDK1 Tyr15 dephosphorylation, delayed G/M progression, and induced caspase-dependent apoptosis with DNA damage. Cytotoxic potency correlated with baseline CDC25C expression, confirming on-target activity. Notably, efficacy was validated in colorectal cancer patient-derived organoids, providing clinically relevant insights into patient-specific responses. Together, these findings define a new class of CDC25 inhibitors with potent and selective anticancer activity, advancing prospects for next-generation therapeutics in leukemia and colorectal cancer.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

… 외 1개

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반